Novel serine threonine kinase member, h2520-59

Abstract

The present invention relates to a serine threonine kinase. The invention also relates to nucleic acids encoding the kinase, vectors, host cells, antibodies and recombinant methods for producing the h2520-59 polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for h2520-59 and related products.

1 - 24 . (canceled)  
     
     
         25 . An antibody produced by immunizing an animal with a peptide comprising an amino acid sequence of SEQ ID NO: 2.  
     
     
         26 . An antibody or fragment thereof that specifically binds the polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.  
     
     
         27 . The antibody of  claim 26  that is a monoclonal antibody.  
     
     
         28 . A hybridoma that produces a monoclonal antibody that binds to a peptide comprising an amino acid sequence of SEQ ID NO: 2.  
     
     
         29 . A method of detecting or quantitating the amount of h2520-59 polypeptide in a sample comprising contacting a sample suspected of containing h2520-59 polypeptide with the anti-h2520-59 antibody or antibody fragment of any of claims  25 ,  26 , or  27  and detecting the binding of said antibody or antibody fragment.  
     
     
         30 . A selective binding agent or fragment thereof that specifically binds at least one polypeptide wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2.  
     
     
         31 . (canceled)  
     
     
         32 . The selective binding agent of  claim 30  that is a humanized antibody.  
     
     
         33 . The selective binding agent of  claim 30  that is a human antibody or fragment thereof.  
     
     
         34 . The selective binding agent of  claim 30  that is a polyclonal antibody or fragment thereof.  
     
     
         35 . The selective binding agent of  claim 30  that is a monoclonal antibody or fragment thereof.  
     
     
         36 . The selective binding agent of  claim 30  that is a chimeric antibody or fragment thereof.  
     
     
         37 . The selective binding agent of  claim 30  that is a complementarity determining region (CDR)-grafted antibody or fragment thereof.  
     
     
         38 . The selective binding agent of  claim 30  that is an anti-idiotypic antibody or fragment thereof.  
     
     
         39 . The selective binding agent of  claim 30  which is an antibody variable region fragment.  
     
     
         40 . The variable region fragment of  claim 39  which is a Fab or a Fab′ fragment.  
     
     
         41 . A selective binding agent or fragment thereof comprising at least one complementarity determining region with specificity for a polypeptide having the amino acid sequence of SEQ ID NO: 2.  
     
     
         42 . The selective binding agent of  claim 30  which is bound to a detectable label.  
     
     
         43 . The selective binding agent of  claim 30  which antagonizes h2520-59 polypeptide biological activity.  
     
     
         44 . A method for treating, preventing, or ameliorating a disease, condition, or disorder comprising administering to a patient an effective amount of a selective binding agent according to  claim 30 .  
     
     
         45 . A selective binding agent produced by immunizing an animal with a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.  
     
     
         46 . A hybridoma that produces a selective binding agent capable of binding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.  
     
     
         47 - 78 . (canceled)  
     
     
         79 . A selective binding agent that specifically binds a first polypeptide with an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, and antagonizes the binding of the first polypeptide to an activating transcription factor-4 (ATF-4) polypeptide.  
     
     
         80 . The selective binding agent of  claim 79  that is an antibody or fragment thereof.  
     
     
         81 . The selective binding agent of  claim 79  that is a humanized antibody.  
     
     
         82 . The selective binding agent of  claim 79  that is a human antibody or fragment thereof.  
     
     
         83 . The selective binding agent of  claim 79  that is a polyclonal antibody or fragment thereof.  
     
     
         84 . The selective binding agent of  claim 79  that is a monoclonal antibody or fragment thereof.  
     
     
         85 . The selective binding agent of  claim 79  that is a chimeric antibody or fragment thereof.  
     
     
         86 . The selective binding agent of  claim 79  that is a complementarity determining region (CDR)-grafted antibody or fragment thereof.  
     
     
         87 . The selective binding agent of  claim 79  that is an anti-idiotypic antibody or fragment thereof.  
     
     
         88 . The selective binding agent of  claim 79  which is an antibody variable region fragment.  
     
     
         89 . The selective binding agent of  claim 88  wherein the variable region fragment is a Fab or a Fab′ fragment.  
     
     
         90 . The selective binding agent of  claim 79  which is bound to a detectable label.